BioAge Labs doses first participant in QUELL-DME Phase 2
BioAge Labs says the first participant was dosed in QUELL-DME, a Phase 2 trial of BGE-102 in diabetic macular edema.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.